Abstracts tagged "Health Care"

Abstract Number: 2216 • ACR Convergence 2024
Additive Impact of Rheumatoid Arthritis and HBcAb+ on All-cause and Cardiovascular Mortality
Leiyi Yang¹, Bo Chen², Qibing Xie³ and Geng Yin⁴, ¹Sichuan University, Cheng Du Shi, Sichuan, China (People's Republic), ²Chenbo, Chendu, Sichuan, China, ³Department of Rheumatology and Immunology, Chengdu, Sichuan, China, ⁴Department of Rheumatology and Immunology, chengdu, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) and hepatitis B both have a high incidence and significant health impacts, possibly sharing a pathogenic connection. Notably, a considerable proportion of…
Abstract Number: 0366 • ACR Convergence 2024
Factors Associated with Participation in Rheumatology Clinical Trials: A UK-based Study
Koushan Kouranloo¹ and Chris Wincup², ¹Internal Medicine Resident., London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Clinicians are encouraged to consider patient preferences for offering face-to-face vs virtual consultations. This adaptability is particularly important to rheumatologists caring for patients with…
Abstract Number: 1402 • ACR Convergence 2024
Addressing Unmet Needs in Cannabis and Hemp by Improving Knowledge and Data Collection
Jahan Marcu¹, Philip Molloy², Kayla Pray³ and Teresa Simon⁴, ¹Marcu Enterprises/ Physicians Research Center, Jersey City, NJ, ²Physicians Research Center,LLC, Carver, MA, ³Physicians Research Center,LLC, Farmingdale, NJ, ⁴Physicians Research Center,LLC, Toms River, NJ
Background/Purpose: Cannabis and its derivatives are increasingly integrated into treatments for rheumatic diseases, yet there is a significant lack of evidence and systematic data collection…
Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Mohammad Movahedi¹, Elliot Hepworth², Angela Cesta³, Xiuying Li³, Claire Bombardier⁴ and Sibel Aydin⁵, and OBRI investogators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
Abstract Number: 0375 • ACR Convergence 2024
Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
Jasvinder Singh¹, Larry Hearld², Walter Chatham³, Sonali Narain⁴, Narender Annapureddy⁵, Diane Kamen⁶, Kimberly Trotter⁷, vikas Majithia⁸, Zineb Aouhab⁹, Swamy Venuturupalli¹⁰, Daniel Wallace¹¹, rosalind Ramsey-Goldman¹², Alfred Kim¹³, Maureen McMahon¹⁴, S. Sam Lim¹⁵, Kalpana Bhairavarasu¹⁶, Alexa Meara¹⁷, Kenneth Kalunian¹⁸ and Cathy Lee Ching¹⁹, ¹Baylor College of Medicine, Birmingham, AL, ²University of Alabama at Birmingham (UAB), Birmingham, AL, ³University of Nevada, Las Vegas, Las Vegas, NV, ⁴Northwell Health, Great Neck, NY, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Chicago, Chicago, IL, ⁸University of Missisippi Medical Center (UMC), Jackson, MS, ⁹Loyola University Medical Center, Oak Brook, IL, ¹⁰Attune Health, Beverly Hills, CA, ¹¹Cedars Sinai Medical Center, Studio City, CA, ¹²Northwestern University, Chicago, IL, ¹³Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁴UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁵Emory University, Atlanta, GA, ¹⁶Baylor College of Medicine, Sugar Land, TX, ¹⁷The Ohio State University Wexner Medical Center, COLUMBUS, OH, ¹⁸University of California San Diego, La Jolla, CA, ¹⁹UMMC, Jackson, MS
Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 2273 • ACR Convergence 2024
Time-Trends in Real-World Glucocorticoid Treatment Strategies in Patients with Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort(CATCH) Study
Orit Schieir¹, Marie-France Valois², Louis Bessette³, Carter Thorne⁴, Gilles Boire⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁴, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators., ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³University of Laval, Quebec City, QC, Canada, ⁴Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁵Retired, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Increased availability of a wider array of effective RA treatments and evidence of glucocorticoid (GC)-related adverse events have prompted updated recommendations limiting GC use…
Abstract Number: 0433 • ACR Convergence 2024
Male Perspective on Reproductive Health in Rheumatology Patients: A Cross-sectional Study
Eleonora Giacobbe¹, Maria Chiara Gerardi², Clizia Gagliardi², Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Milan, Lombardia, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: As reproductive health is gathering attention in rheumatology and all medical fields, the male perspective on the matter is often overlooked as not directly…
Abstract Number: 1625 • ACR Convergence 2024
Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
Alae Dhahbi¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Sélène Meunier², Hussein Baalbaki², Carolyn Ross⁴ and Jean-Paul Makhzoum⁴, ¹Laval University, Quebec, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Sherbrooke, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background/Purpose: Giant cell arteritis (GCA) is both a medical emergency and diagnostic challenge. Up to 45% of patients may require emergency department (ED) visits and/or…
Abstract Number: 2337 • ACR Convergence 2024
Patient Characteristics and Outcomes of Emergency Visits in Psoriatic Arthritis: Results from the U.S. Nationwide Emergency Department Sample (NEDS)
Dominique Feterman Jimenez¹, Rachael Stovall¹, Jose Andres Porres Arnaez², Vishwesh Bharadiya³, Jean Liew⁴, Alison Bays¹, Thomason Jenna⁵, Londyn Robinson⁶, Rashmi Dhital⁷ and Namrata Singh⁸, ¹University of Washington, Seattle, WA, ²Universidad Francisco Marroquin, Guatemala, ³AIIMS, New Delhi, India, ⁴Boston University, Boston, MA, ⁵University of Washington, Division of Rheumatology, Seattle, WA, ⁶University of Washington, Durham, NC, ⁷UC San Diego, Brentwood, TN, ⁸University of Washington, Bellevue, WA
Background/Purpose: Compared with the general population, patients with psoriatic arthritis (PsA) have a higher risk of comorbidities and all-cause mortality. They are also at increased…
Abstract Number: 0614 • ACR Convergence 2024
Bridging the Gap Between Patient’s Perception on Quality of Life and Disease Activity and Damage in Systemic Lupus Erythematous Patient
Background/Purpose: Improving quality of life (QoL) is one of the key targets when treating systemic lupus erythematosus (SLE) patients. The Lupus impact Tracker (LIT) is…
Abstract Number: 1717 • ACR Convergence 2024
Early Antimalarial Adherence Reduces Future Hospitalization Cost in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: Evidence from a Population-based Study
Md Rashedul Hoque¹, Diane Lacaille², J. Antonio Avina-Zubieta², Mary A. De Vera³, Yi Qian⁴, John Esdaile⁵ and Hui Xie⁶, ¹Simon Fraser University, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³University of British Columbia, Faculty of Pharmaceutical Sciences, Vancouver, BC, Canada, ⁴University of British Columbia, Vancouver, Canada, ⁵Arthritis Research Canada, Vancouver, BC, Canada, ⁶Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada
Background/Purpose: To examine the association between antimalarial (AM) adherence and hospitalization costs among newly diagnosed rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.Methods: We…
Abstract Number: 2519 • ACR Convergence 2024
What Do We Know About Malignancies in IgA Vasculitis?
Alojzija Hocevar¹, Jaka Ostrovrsnik², vesna Jurcic³ and Ziga Rotar⁴, ¹University Medical Center Ljubljana, LJUBLJANA, Slovenia, ²UMC Ljubljana, Dpt. of Rheumatology, Ljubljana, Slovenia, ³Medical Faculty, University of Ljubljana, Institute of pathology, Ljubljana, Slovenia, ⁴University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Cancer has been reported as a potential trigger of IgA vasculitis (IgAV) in adults, however data on this topic is scarce. The aim of…
Abstract Number: 0615 • ACR Convergence 2024
Socioeconomic Determinants of Lupus Hospitalization Outcomes: A Review of Current Knowledge and Analysis of the 2016-2019 NRD Database
Akhila Arya P V¹, Madhumitha Rondla², Jai Juganya Tirupur Ponnusamy³ and Dileep C Unnikrishnan⁴, ¹Bridgeport Hospital, Stratford, CT, ²Texas tech university health sciences center, El paso, El Paso, TX, ³Metrowest Medical Center, Framingham, ⁴Bridgeport Hospital, Bridgeport, CT
Background/Purpose: Hospitalizations due to systemic lupus erythematosus (SLE) often stem from lupus flares and infections. Socioeconomic factors influencing outcomes in SLE hospitalizations have been studied…
Abstract Number: 1870 • ACR Convergence 2024
Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France
Nicoleta Petrica¹, Nathan Cohen¹, Maria Pini¹, Minjee Park², Mathieu Rosé³ and Jean-Francois Ricci², ¹Alira Health, Paris, France, ²Alira Health, Basel, Switzerland, ³Alira Health, Barcelone, Spain
Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].